We are live on
!
Find out more
VP
Vitruvian Partners Portfolio holdings
AUM
$112M
1-Year Est. Return
2.02%
This Fund
S&P 500
This Quarter
Est. Return
-37.57%
1 Year Est. Return
+2.02%
3 Year Est. Return
+35.84%
5 Year Est. Return
+18.92%
10 Year Est. Return
–
AUM
$590M
AUM Growth
-$353M
(-37%)
Cap. Flow
+$3.24M
Cap. Flow
% of AUM
0.55%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
1
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MaxCyte
MXCT
|
+$3.24M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 58.66% |
| 2 | Technology | 32.65% |
| 3 | Industrials | 4.65% |
| 4 | Healthcare | 4.05% |
Similar funds
RTM
JE
GW
SPWM
OCA
APFP
FCU
DM
Vitruvian Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Vitruvian Partners held 8 positions worth $590M, down 37% from $942M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Trading was light in Q2 2022: portfolio turnover was 0%. Vitruvian Partners opened no new positions and made no exits, leaving the 8-position portfolio largely intact.
By sector, the portfolio is most concentrated in Consumer Discretionary at 59% of assets, down from 62% a quarter earlier, followed by Technology and Industrials.
- Vitruvian Partners added most to MaxCyte in Q2 2022, an estimated $3.24M increase.
- Vitruvian Partners's ten largest holdings make up 100% of its $590M portfolio in Q2 2022.
- Vitruvian Partners opened 0 new positions and closed 0 in Q2 2022.
- Vitruvian Partners's portfolio value fell 37% quarter-over-quarter to $590M.
Based on Vitruvian Partners's 13F filing for Q2 2022, filed 14 Jul 2022.